# UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

> **NCT00083551** · PHASE3 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 668 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Ara-C
- **DRUG:** BCNU
- **DRUG:** Cisplatin
- **DRUG:** Cytoxan
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Filgrastim
- **DRUG:** Recombinant GM-CSF
- **DRUG:** Interferon-alpha-2b
- **DRUG:** Melphalan
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00083551
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2015-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083551, "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00083551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*